MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Akerna Corp. Balance Sheet 2011-2026 | KERN
Annual Balance Sheet Akerna Corp.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | 13.7 M | 3.37 M | -7.82 M | -21.9 M | -4.49 K | 105 K | - | - | - | - | - | - |
Long Term Debt |
- | - | 1.41 M | 4.1 M | 10.2 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | 13.2 M | 13.2 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 10.2 M | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
9.26 M | 19.4 M | 22.5 M | 29.2 M | 15.7 M | 2.44 M | 1.39 M | - | - | - | - | - | - | - |
Total Liabilities |
14.6 M | 19.4 M | 24.3 M | 34.5 M | 22 M | 2.44 M | 392 K | 136 K | - | - | - | - | - | - |
Deferred Revenue |
- | - | 569 K | 3.54 M | 369 K | 624 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-67.7 M | -47.2 M | -168 M | -88.5 M | -41.1 M | -25.2 M | -31.5 K | -1.56 K | - | - | - | - | - | - |
Total Assets |
7.63 M | 18.8 M | 19.5 M | 94.5 M | 58.5 M | 24.5 M | 58.5 M | 160 K | - | - | - | - | - | - |
Cash and Cash Equivalents |
735 K | 915 K | 878 K | 13.9 M | 17.8 M | 21.9 M | 2.57 M | - | - | - | - | - | - | - |
Book Value |
-7.01 M | -599 K | -4.83 M | 59.9 M | 36.6 M | 22.1 M | 58.1 M | 23.4 K | - | - | - | - | - | - |
Total Shareholders Equity |
-7.01 M | -599 K | -4.83 M | 59.9 M | 57.2 M | 21.8 M | 1.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Akerna Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
145 M | - | - | - | - | - | - | - | 7.73 M | 2.49 M | 1.58 M | 1.41 M | 4.58 M | 6.79 M | 2.14 M | 4.1 M | 3.83 M | 1.2 M | - | 3.9 M | 3.9 M | 3.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
439 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
587 M | 17.2 M | 16.6 M | 14.6 M | - | 25.4 M | - | 19.4 M | 13.4 M | 14.6 M | 12.8 M | 24.3 M | 25.5 M | 30.2 M | 33.6 M | 34.5 M | 10.1 M | 14.6 M | 14.6 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | - | - | 5.48 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 470 K | 313 K | 517 K | 569 K | 2.15 M | 2.4 M | 3.37 M | 3.54 M | 908 K | 1.18 M | 1.11 M | 844 K | 844 K | 844 K | 844 K | 845 K | 903 K | 624 K | 624 K | - | - | 470 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
6.91 M | -79.3 M | -74 M | -67.7 M | -68.1 M | -62.2 M | - | -47.2 M | -176 M | -173 M | -170 M | -168 M | -142 M | -140 M | -110 M | -88.5 M | -71.3 M | -69.7 M | -63.6 M | -57.2 M | -57.2 M | -57.2 M | -57.2 M | -32.8 M | -28.4 M | -27.6 M | -25.6 M | - | - | -12.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.16 B | 6.2 M | 8.98 M | 7.63 M | 7.54 M | 11.4 M | - | 18.8 M | 4.18 M | 6.41 M | 7 M | 19.5 M | 45.6 M | 43.2 M | 74.3 M | 94.5 M | 74.5 M | 76.5 M | 74.3 M | 77.2 M | 77.2 M | 77.2 M | 77.2 M | 22.4 M | 24.2 M | 24.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
7.98 M | 678 K | 318 K | 735 K | 368 K | 1.22 M | 1.74 M | 915 K | 1.4 M | 960 K | 882 K | 878 K | 9.5 M | 5.13 M | 10.2 M | 13.9 M | 10.1 M | 12.3 M | 15.4 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 18.8 M | 22.4 M | 21.9 M | 21.9 M | 9.08 M | 11.6 M | 1.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
575 M | -11 M | -7.66 M | -7.01 M | - | -14 M | - | -599 K | -9.2 M | -8.16 M | -5.79 M | -4.83 M | 20.1 M | 12.9 M | 40.8 M | 59.9 M | 64.4 M | 62 M | 59.8 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 22.4 M | 24.2 M | 18.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
575 M | -11 M | -7.66 M | -7.01 M | 698 M | -14 M | -12.4 M | -599 K | 10.1 M | 17.9 M | -5.79 M | -4.83 M | 20.1 M | 12.9 M | 40.8 M | 59.9 M | 64.4 M | 62 M | 59.8 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 19.3 M | 23.3 M | -19.3 M | 23.3 M | 7.31 M | 9.7 M | 1.4 M | - | - | - | 3.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Akerna Corp., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M |  USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.1 | -9.5 % | $ 76.9 M | USA |
 |
American Well Corporation
AMWL
|
$ 5.76 | -0.52 % | $ 92.4 M | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
HealthStream
HSTM
|
$ 20.97 | -0.76 % | $ 637 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Omnicell
OMCL
|
$ 34.46 | 0.44 % | $ 1.59 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 6.78 | 5.44 % | $ 116 M | USA |
 |
HealthEquity
HQY
|
$ 82.1 | 0.56 % | $ 7.07 B | USA |
 |
Phreesia
PHR
|
$ 11.28 | -4.41 % | $ 615 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Evolent Health
EVH
|
$ 2.25 | -9.64 % | $ 211 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.04 | -1.92 % | $ 787 M | USA |
 |
Schrödinger
SDGR
|
$ 11.57 | -2.53 % | $ 850 M | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
Teladoc Health
TDOC
|
$ 5.42 | -1.09 % | $ 955 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Zhongchao
ZCMD
|
$ 1.81 | -4.23 % | $ 9.42 M |  China |
 |
10x Genomics
TXG
|
$ 19.81 | 3.5 % | $ 2.32 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
$ 0.13 | -4.16 % | $ 190 K | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Progyny
PGNY
|
$ 18.05 | 0.22 % | $ 1.55 B | USA |
 |
So-Young International
SY
|
$ 2.91 | - | $ 231 M | China |
 |
Veeva Systems
VEEV
|
$ 179.11 | -3.3 % | $ 29.3 B | USA |